JP2013503607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503607A5 JP2013503607A5 JP2012527113A JP2012527113A JP2013503607A5 JP 2013503607 A5 JP2013503607 A5 JP 2013503607A5 JP 2012527113 A JP2012527113 A JP 2012527113A JP 2012527113 A JP2012527113 A JP 2012527113A JP 2013503607 A5 JP2013503607 A5 JP 2013503607A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- disease
- binding protein
- mtx
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000023732 binding proteins Human genes 0.000 claims 69
- 108091008324 binding proteins Proteins 0.000 claims 69
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 50
- 229960000485 methotrexate Drugs 0.000 claims 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- 201000010099 disease Diseases 0.000 claims 16
- 208000011580 syndromic disease Diseases 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 12
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 208000019693 Lung disease Diseases 0.000 claims 10
- 230000001154 acute effect Effects 0.000 claims 10
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 9
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 9
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 9
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 9
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 9
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 8
- 210000000056 organ Anatomy 0.000 claims 8
- 206010020751 Hypersensitivity Diseases 0.000 claims 7
- 230000001684 chronic effect Effects 0.000 claims 7
- 230000001363 autoimmune Effects 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 6
- 201000004624 Dermatitis Diseases 0.000 claims 5
- 206010052779 Transplant rejections Diseases 0.000 claims 5
- 208000026935 allergic disease Diseases 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 208000015181 infectious disease Diseases 0.000 claims 5
- 230000002757 inflammatory effect Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 238000002054 transplantation Methods 0.000 claims 5
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 4
- 206010015150 Erythema Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 4
- 231100000321 erythema Toxicity 0.000 claims 4
- 208000006454 hepatitis Diseases 0.000 claims 4
- 231100000283 hepatitis Toxicity 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000026872 Addison Disease Diseases 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 206010034277 Pemphigoid Diseases 0.000 claims 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 3
- 208000031845 Pernicious anaemia Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 206010003119 arrhythmia Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000018631 connective tissue disease Diseases 0.000 claims 3
- 239000002872 contrast media Substances 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000000684 flow cytometry Methods 0.000 claims 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 3
- 208000007475 hemolytic anemia Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 3
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 3
- 230000003902 lesion Effects 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 238000006386 neutralization reaction Methods 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 230000000414 obstructive effect Effects 0.000 claims 3
- 201000004535 ovarian dysfunction Diseases 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 210000003491 skin Anatomy 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000000659 Autoimmune lymphoproliferative syndrome Diseases 0.000 claims 2
- 208000015879 Cerebellar disease Diseases 0.000 claims 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 208000017701 Endocrine disease Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 208000036066 Hemophagocytic Lymphohistiocytosis Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 206010020880 Hypertrophy Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 2
- 208000016604 Lyme disease Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 208000012287 Prolapse Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010062164 Seronegative arthritis Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 230000003444 anaesthetic effect Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- -1 anthracyclines Substances 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 238000010322 bone marrow transplantation Methods 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 230000009033 hematopoietic malignancy Effects 0.000 claims 2
- 230000036039 immunity Effects 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 230000000366 juvenile effect Effects 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000020763 muscle atrophy Effects 0.000 claims 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000015124 ovarian disease Diseases 0.000 claims 2
- 231100000543 ovarian dysfunction Toxicity 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000002574 reactive arthritis Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000009174 transverse myelitis Diseases 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- 208000023769 AA amyloidosis Diseases 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003226 Arteriovenous fistula Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 208000006740 Aseptic Meningitis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 206010003671 Atrioventricular Block Diseases 0.000 claims 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims 1
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 1
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims 1
- 208000022106 Autoimmune polyendocrinopathy type 2 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006448 Bronchiolitis Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000000135 Cardiovascular Syphilis Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims 1
- 241000606161 Chlamydia Species 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 201000003874 Common Variable Immunodeficiency Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010010941 Coombs positive haemolytic anaemia Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011703 Cyanosis Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 206010012310 Dengue fever Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000006926 Discoid Lupus Erythematosus Diseases 0.000 claims 1
- 208000002251 Dissecting Aneurysm Diseases 0.000 claims 1
- 102000015554 Dopamine receptor Human genes 0.000 claims 1
- 108050004812 Dopamine receptor Proteins 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010072268 Drug-induced liver injury Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 208000035366 Familial hemophagocytic lymphohistiocytosis Diseases 0.000 claims 1
- 208000007984 Female Infertility Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010058872 Fungal sepsis Diseases 0.000 claims 1
- 201000000628 Gas Gangrene Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018498 Goitre Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000031856 Haemosiderosis Diseases 0.000 claims 1
- 208000025309 Hair disease Diseases 0.000 claims 1
- 206010019315 Heart transplant rejection Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000037147 Hypercalcaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010021928 Infertility female Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims 1
- 206010058142 Intestine transplant rejection Diseases 0.000 claims 1
- 206010022941 Iridocyclitis Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 1
- 241000589248 Legionella Species 0.000 claims 1
- 208000007764 Legionnaires' Disease Diseases 0.000 claims 1
- 208000004554 Leishmaniasis Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000012309 Linear IgA disease Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010024715 Liver transplant rejection Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025282 Lymphoedema Diseases 0.000 claims 1
- 208000035809 Lymphohistiocytosis Diseases 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027201 Meningitis aseptic Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 241000186359 Mycobacterium Species 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 206010028665 Myxoedema Diseases 0.000 claims 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 208000003076 Osteolysis Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033165 Ovarian failure Diseases 0.000 claims 1
- 206010053869 POEMS syndrome Diseases 0.000 claims 1
- 206010049169 Pancreas transplant rejection Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 208000008223 Pemphigoid Gestationis Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000025584 Pericardial disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 claims 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 206010057244 Post viral fatigue syndrome Diseases 0.000 claims 1
- 206010052381 Primary adrenal insufficiency Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 206010037549 Purpura Diseases 0.000 claims 1
- 241001672981 Purpura Species 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010037779 Radiculopathy Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 201000003099 Renovascular Hypertension Diseases 0.000 claims 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010038915 Retinitis viral Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039094 Rhinitis perennial Diseases 0.000 claims 1
- 241000607142 Salmonella Species 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 206010039807 Secondary adrenocortical insufficiency Diseases 0.000 claims 1
- 206010039811 Secondary amyloidosis Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000009714 Severe Dengue Diseases 0.000 claims 1
- 208000032384 Severe immune-mediated enteropathy Diseases 0.000 claims 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 1
- 208000006045 Spondylarthropathies Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010061372 Streptococcal infection Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 241000607734 Yersinia <bacteria> Species 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000018254 acute transverse myelitis Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000030597 adult Refsum disease Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000002226 anterior horn cell Anatomy 0.000 claims 1
- 201000004612 anterior uveitis Diseases 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003092 anti-cytokine Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000002682 anti-psoriatic effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003080 antimitotic agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 210000000702 aorta abdominal Anatomy 0.000 claims 1
- 206010002895 aortic dissection Diseases 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 206010003668 atrial tachycardia Diseases 0.000 claims 1
- 208000001974 autoimmune enteropathy Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000009780 autoimmune polyendocrine syndrome type 2 Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 208000018300 basal ganglia disease Diseases 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 210000004375 bundle of his Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 208000036319 cervical spondylosis Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000007870 cholestasis Effects 0.000 claims 1
- 231100000359 cholestasis Toxicity 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000002594 corticospinal effect Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000000139 costimulatory effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000000430 cytokine receptor antagonist Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000002950 dengue hemorrhagic fever Diseases 0.000 claims 1
- 201000011304 dilated cardiomyopathy 1A Diseases 0.000 claims 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008865 drug-induced hepatitis Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 210000000918 epididymis Anatomy 0.000 claims 1
- 201000010063 epididymitis Diseases 0.000 claims 1
- 210000002409 epiglottis Anatomy 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108010074605 gamma-Globulins Proteins 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 201000003872 goiter Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 201000010235 heart cancer Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000024348 heart neoplasm Diseases 0.000 claims 1
- 208000018578 heart valve disease Diseases 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 208000014752 hemophagocytic syndrome Diseases 0.000 claims 1
- 231100000753 hepatic injury Toxicity 0.000 claims 1
- 208000005252 hepatitis A Diseases 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000000148 hypercalcaemia Effects 0.000 claims 1
- 208000030915 hypercalcemia disease Diseases 0.000 claims 1
- 230000001660 hyperkinetic effect Effects 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000003483 hypokinetic effect Effects 0.000 claims 1
- 208000003532 hypothyroidism Diseases 0.000 claims 1
- 230000002989 hypothyroidism Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 201000008319 inclusion body myositis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 208000037797 influenza A Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007919 intrasynovial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 201000004614 iritis Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 claims 1
- 231100001022 leukopenia Toxicity 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002502 lymphedema Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000029791 lytic metastatic bone lesion Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 208000003786 myxedema Diseases 0.000 claims 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 239000000842 neuromuscular blocking agent Substances 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 231100000539 ovarian failure Toxicity 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 claims 1
- 230000003071 parasitic effect Effects 0.000 claims 1
- 230000000849 parathyroid Effects 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 208000015385 phacoanaphylactic uveitis Diseases 0.000 claims 1
- 208000001297 phlebitis Diseases 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 201000000317 pneumocystosis Diseases 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 208000019629 polyneuritis Diseases 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 208000000813 polyradiculoneuropathy Diseases 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000010349 pulsation Effects 0.000 claims 1
- 239000012217 radiopharmaceutical Substances 0.000 claims 1
- 229940121896 radiopharmaceutical Drugs 0.000 claims 1
- 230000002799 radiopharmaceutical effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000000552 rheumatic effect Effects 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 208000004124 rheumatic heart disease Diseases 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000003786 sclera Anatomy 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
- 208000023087 secondary adrenal insufficiency Diseases 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000005801 spondylosis Diseases 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 230000002992 thymic effect Effects 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 claims 1
- 230000005951 type IV hypersensitivity Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
- 230000003156 vasculitic effect Effects 0.000 claims 1
- 208000037997 venous disease Diseases 0.000 claims 1
- 238000009423 ventilation Methods 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23890809P | 2009-09-01 | 2009-09-01 | |
| US61/238,908 | 2009-09-01 | ||
| US25194609P | 2009-10-15 | 2009-10-15 | |
| US61/251,946 | 2009-10-15 | ||
| PCT/US2010/047543 WO2011028811A2 (en) | 2009-09-01 | 2010-09-01 | Dual variable domain immunoglobulins and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013503607A JP2013503607A (ja) | 2013-02-04 |
| JP2013503607A5 true JP2013503607A5 (https=) | 2013-10-31 |
Family
ID=43649948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012527113A Withdrawn JP2013503607A (ja) | 2009-09-01 | 2010-09-01 | 二重可変ドメイン免疫グロブリンおよびその使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8586714B2 (https=) |
| EP (1) | EP2473524A4 (https=) |
| JP (1) | JP2013503607A (https=) |
| KR (1) | KR20120060877A (https=) |
| CN (1) | CN102612524A (https=) |
| AR (1) | AR078254A1 (https=) |
| AU (1) | AU2010289527C1 (https=) |
| BR (1) | BR112012004710A2 (https=) |
| CA (1) | CA2772628A1 (https=) |
| CL (1) | CL2012000559A1 (https=) |
| CO (1) | CO6511254A2 (https=) |
| CR (1) | CR20120154A (https=) |
| DO (1) | DOP2012000055A (https=) |
| EC (1) | ECSP12011730A (https=) |
| GT (1) | GT201200058A (https=) |
| IL (1) | IL218402A0 (https=) |
| IN (1) | IN2012DN02737A (https=) |
| MX (1) | MX2012002651A (https=) |
| NZ (1) | NZ598929A (https=) |
| PE (1) | PE20121530A1 (https=) |
| RU (1) | RU2012112550A (https=) |
| SG (1) | SG178602A1 (https=) |
| TW (1) | TW201119673A (https=) |
| UY (1) | UY32870A (https=) |
| WO (1) | WO2011028811A2 (https=) |
| ZA (1) | ZA201202268B (https=) |
Families Citing this family (154)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0910482A2 (pt) * | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| BRPI0913366A8 (pt) * | 2008-06-03 | 2017-07-11 | Abbott Lab | Imunoglobulinas de domínio variável duplo e seus usos |
| PE20100092A1 (es) * | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
| NZ603698A (en) * | 2008-07-08 | 2014-03-28 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| WO2011025964A2 (en) | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| KR20120060877A (ko) * | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| AU2010306677B2 (en) * | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| ES2700450T3 (es) | 2009-10-16 | 2019-02-15 | Oncomed Pharm Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| BR112012021941A2 (pt) | 2010-03-02 | 2022-02-01 | Abbvie Inc | Proteínas terapêuticas de ligação a dll4 |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| PE20140229A1 (es) | 2010-08-26 | 2014-03-27 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US20120263722A1 (en) * | 2010-11-04 | 2012-10-18 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| DK3252076T3 (da) | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
| CN105884900A (zh) | 2011-04-19 | 2016-08-24 | 梅里麦克制药股份有限公司 | 单特异性和双特异性抗igf-1r和抗erbb3抗体 |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| AR089529A1 (es) | 2011-12-30 | 2014-08-27 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17 |
| BR112014016299A8 (pt) * | 2011-12-30 | 2017-07-04 | Abbvie Inc | imunoglobulinas de domínio variável e usos das mesmas |
| CA2865415C (en) | 2012-02-24 | 2022-06-21 | Stem Centrx, Inc. | Anti sez6 antibodies and methods of use |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| HK1212448A1 (en) | 2012-09-07 | 2016-06-10 | The Governors Of The University Of Alberta | Methods and compositions for diagnosis of inflammatory liver disease |
| ES2649990T3 (es) * | 2012-10-12 | 2018-01-16 | Medimmune Limited | Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas |
| CN104837502B (zh) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| DK2906298T3 (en) | 2012-10-12 | 2018-12-17 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| AU2013328625B2 (en) | 2012-10-12 | 2016-12-15 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
| US9217042B2 (en) * | 2012-10-23 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Method of reducing MACE in diabetic patients subsequent to stent placement |
| US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| KR20180008921A (ko) | 2012-11-01 | 2018-01-24 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| CN113201073A (zh) | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| US20170275367A1 (en) | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| CN105143272A (zh) * | 2013-02-05 | 2015-12-09 | 赛诺菲 | 用于与抗体药物偶联物疗法一起使用的免疫成像剂 |
| US9989524B2 (en) | 2013-02-05 | 2018-06-05 | Sanofi | Immuno imaging agent for use with antibody-drug conjugate therapy |
| RU2015137858A (ru) * | 2013-02-05 | 2017-03-13 | Санофи | Иммунологическое визуализирующее средство для использования при терапии коньюгатом антитело-лекарственное средство |
| JP2016515093A (ja) | 2013-02-05 | 2016-05-26 | サノフイ | 抗体−薬物コンジュゲート療法とともに使用するための免疫イメージング剤 |
| CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
| KR20220041957A (ko) * | 2013-03-15 | 2022-04-01 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 항-egfr 항체 약물 접합체 제형 |
| RU2652880C2 (ru) * | 2013-04-07 | 2018-05-03 | Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. | Антитело против рецептора эпидермального фактора роста |
| CN105722859B (zh) | 2013-07-25 | 2021-05-07 | 西托姆克斯治疗公司 | 多特异性抗体、多特异性可活化抗体及其使用方法 |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054986B1 (en) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EP3099717B1 (en) | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| WO2015120389A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers treatment for systemic disorders |
| PL3104854T3 (pl) | 2014-02-10 | 2020-11-30 | Respivant Sciences Gmbh | Stabilizatory komórek tucznych do leczenia choroby płuc |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| BR112016030740A2 (pt) | 2014-07-01 | 2018-02-20 | Pfizer Inc. | diacorpos heterodiméricos biespecíficos e seus usos |
| WO2016014725A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
| JP7020909B2 (ja) | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| ES2771926T3 (es) | 2014-09-13 | 2020-07-07 | Novartis Ag | Terapias de combinación |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| SG11201704741PA (en) * | 2014-12-22 | 2017-07-28 | Systimmune Inc | Bispecific tetravalent antibodies and methods of makiing and using thereof |
| US10744157B2 (en) | 2015-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3294761A4 (en) * | 2015-05-13 | 2019-04-03 | University of Washington | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF UROPATHOGEN E. COLI |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| DK3317301T3 (da) | 2015-07-29 | 2021-06-28 | Immutep Sas | Kombinationsterapier omfattende antistofmolekyler mod lag-3 |
| WO2017027387A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| EP3423105B1 (en) | 2016-03-02 | 2021-05-05 | Eisai R&D Management Co., Ltd. | Eribulin-based antibody-drug conjugates and methods of use |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| EP3506893A4 (en) | 2016-08-31 | 2020-01-22 | Respivant Sciences GmbH | CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS |
| JP2019531308A (ja) | 2016-10-07 | 2019-10-31 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 肺線維症の治療のためのクロモリン組成物 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| MX375569B (es) | 2017-02-08 | 2025-03-04 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| BR102018006205A2 (pt) | 2017-03-28 | 2021-03-23 | Cell Design Labs, Inc. | Polipeptídeos quiméricos e métodos de alterar a localização da membrana dos mesmos |
| PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
| ES2977788T3 (es) | 2017-04-20 | 2024-08-30 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo anti-AXL y fármaco |
| MX2019015042A (es) | 2017-06-14 | 2020-08-06 | Adc Therapeutics Sa | Regimen de dosificacion. |
| US11325957B2 (en) | 2017-06-19 | 2022-05-10 | Cell Design Labs, Inc. | Methods and compositions for reducing the immunogenicity of chimeric notch receptors |
| DK3668874T3 (da) | 2017-08-18 | 2022-02-14 | Medimmune Ltd | Pyrrolobenzodiazepin-konjugater |
| MX2020006435A (es) | 2017-12-19 | 2021-02-09 | Akouos Inc | Administracion de anticuerpos terapeuticos mediada por vector de virus adenoasociado (aav) en el oido interno. |
| WO2019126358A1 (en) | 2017-12-22 | 2019-06-27 | Cell Design Labs, Inc. | Single- and multi-chain chimeric antigen receptors |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| EP3755712A1 (en) | 2018-02-21 | 2020-12-30 | Cell Design Labs, Inc. | Chimeric transmembrane receptors and uses thereof |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| US20200041518A1 (en) | 2018-08-03 | 2020-02-06 | CellMax Life, Inc. | Lipid vesicle-coated magnetic beads and uses of the same |
| CA3109361A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| US11401324B2 (en) | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| US11518792B2 (en) | 2018-08-30 | 2022-12-06 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CA3118692A1 (en) * | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| KR102890251B1 (ko) | 2019-03-15 | 2025-11-25 | 메드임뮨 리미티드 | 암의 치료에 사용하기 위한 아제티도벤조디아제핀 이량체 및 이를 포함하는 컨쥬게이트 |
| BR112021021099A2 (pt) | 2019-04-23 | 2021-12-14 | Sanofi Sa | Formulações de anticorpos estáveis, de baixa viscosidade, e usos das mesmas |
| EP3966250A4 (en) * | 2019-05-07 | 2022-11-23 | Immunorizon Ltd. | PRECURSOR TRI-SPECIFIC ANTIBODY CONSTRUCTIONS AND METHODS OF USE THEREOF |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| AU2020287378A1 (en) | 2019-06-06 | 2022-02-03 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| EP3980127A1 (en) | 2019-06-06 | 2022-04-13 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| MX2021015095A (es) | 2019-06-07 | 2022-03-22 | Mythic Therapeutics Inc | Construcciones de proteínas de unión a antígenos y usos de estos. |
| CN120924491A (zh) | 2019-06-21 | 2025-11-11 | 免疫生物公司 | 多链嵌合多肽和其用途 |
| US20220306751A1 (en) | 2019-09-13 | 2022-09-29 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| US20220348679A1 (en) | 2019-10-04 | 2022-11-03 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| WO2021141996A1 (en) | 2020-01-06 | 2021-07-15 | Cytomx Therapeutics, Inc. | Single- and multi-chain polypeptides that bind specifically to cd3 epsilon |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| WO2021163299A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Chromatography resin and uses thereof |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| BR112022018987A2 (pt) | 2020-03-26 | 2022-11-01 | Seagen Inc | Métodos de tratamento de mieloma múltiplo |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| JP2023527869A (ja) | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| CN119792512A (zh) | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| PT4288456T (pt) | 2021-02-03 | 2024-11-13 | Mythic Therapeutics Inc | Anticorpos anti-met e suas utilizações |
| AU2022238571A1 (en) | 2021-03-18 | 2023-09-14 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| AU2022254042A1 (en) | 2021-04-07 | 2023-09-14 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and antibodies and uses thereof |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| WO2023019215A1 (en) | 2021-08-11 | 2023-02-16 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases |
| TW202327650A (zh) | 2021-09-23 | 2023-07-16 | 美商思進公司 | 治療多發性骨髓瘤之方法 |
| EP4434548A1 (en) | 2021-11-15 | 2024-09-25 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
| MX2024008529A (es) * | 2022-01-07 | 2024-08-26 | Viridian Therapeutics Inc | Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea. |
| EP4473011A1 (en) | 2022-02-02 | 2024-12-11 | Akouos, Inc. | Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms |
| JP2025508939A (ja) | 2022-03-02 | 2025-04-10 | イミュニティーバイオ インコーポレイテッド | 膵臓癌の治療方法 |
| JP2025511187A (ja) | 2022-04-01 | 2025-04-15 | サイトムエックス セラピューティクス，インク． | Ｃｄ３結合タンパク質及びその使用方法 |
| WO2023201311A1 (en) | 2022-04-13 | 2023-10-19 | HCW Biologics, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
| KR20250004747A (ko) | 2022-04-13 | 2025-01-08 | 이뮤니티바이오, 인크. | 생체 시계 유전자 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드 |
| AU2023272168A1 (en) | 2022-05-19 | 2024-11-21 | Mythic Therapeutics, Inc. | Ptk7-binding proteins with ph-dependent binding and uses thereof |
| JP2025525879A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性基質及びその使用方法 |
| TW202424183A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割受質及其使用方法 |
| US20260042849A1 (en) | 2022-08-01 | 2026-02-12 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
| JP2025525868A (ja) | 2022-08-01 | 2025-08-07 | サイトムエックス セラピューティクス，インク． | プロテアーゼ切断性部分及びその使用方法 |
| AR130079A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Restos escindibles por proteasas, y métodos de uso de los mismos |
| WO2024081729A2 (en) | 2022-10-12 | 2024-04-18 | Mythic Therapeutics, Inc. | Lrrc-15-binding protein constructs and uses thereof |
| AU2024248543A1 (en) | 2023-03-29 | 2025-10-09 | Mythic Therapeutics, Inc. | Trop2-binding proteins and uses thereof |
| EP4724492A1 (en) * | 2023-06-09 | 2026-04-15 | Antengene Biologics Limited | Novel antibodies targeting cd3 and another target and uses thereof |
| EP4731670A2 (en) | 2023-06-23 | 2026-04-29 | Mythic Therapeutics, Inc. | Ph sensitive anti-itgb6 antibodies and uses thereof |
| TW202602929A (zh) | 2024-03-21 | 2026-01-16 | 美商思進公司 | Ｃｄ２５抗體、抗體-藥物共軛體及彼等之用途 |
| TW202602935A (zh) | 2024-04-01 | 2026-01-16 | 美商米西克治療公司 | 抗原結合蛋白構築體及其用途 |
| US20260021192A1 (en) | 2024-07-17 | 2026-01-22 | Topaz Therapeutics, Inc. | Proteins having a covalent warhead |
| WO2026035650A2 (en) | 2024-08-05 | 2026-02-12 | Cytomx Therapeutics, Inc. | Cleavable polypeptides and methods of use thereof |
| WO2026043906A1 (en) | 2024-08-19 | 2026-02-26 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
Family Cites Families (248)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| ATE37983T1 (de) * | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US5128326A (en) * | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4699784A (en) * | 1986-02-25 | 1987-10-13 | Center For Molecular Medicine & Immunology | Tumoricidal methotrexate-antibody conjugate |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5258498A (en) * | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
| WO1990014443A1 (en) | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| WO1991006287A1 (en) | 1989-11-06 | 1991-05-16 | Enzytech, Inc. | Protein microspheres and methods of using them |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AT396939B (de) | 1990-05-29 | 1993-12-27 | Alois Dipl Ing Dr Jungbauer | Komplexes virales antigen von hiv-1 bindendes rekombinantes protein |
| EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP0542810A1 (en) | 1990-08-02 | 1993-05-26 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| JP3306063B2 (ja) | 1990-08-24 | 2002-07-24 | イグジス， インコーポレイテッド | ランダムコドンを有するオリゴヌクレオチドを合成する方法 |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| US5780279A (en) * | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| EP0563296B1 (en) | 1990-12-20 | 1999-03-17 | Ixsys, Inc. | Optimization of binding proteins |
| EP0575485A1 (en) | 1991-03-01 | 1993-12-29 | Dyax Corp. | Process for the development of binding mini-proteins |
| EP0531472B1 (en) | 1991-03-06 | 2003-08-13 | MERCK PATENT GmbH | Humanized monoclonal antibodies |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| WO1992019244A2 (en) | 1991-05-01 | 1992-11-12 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | A method for treating infectious respiratory diseases |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| CA2110799A1 (en) | 1991-06-14 | 1992-12-23 | Arnold H. Horwitz | Microbially-produced antibody fragments and their conjugates |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| EP1291360A1 (en) | 1991-12-13 | 2003-03-12 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| AU6132994A (en) | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| WO1995001997A1 (en) | 1993-07-09 | 1995-01-19 | Smithkline Beecham Corporation | RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN |
| WO1995009917A1 (en) | 1993-10-07 | 1995-04-13 | The Regents Of The University Of California | Genetically engineered bispecific tetravalent antibodies |
| EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| WO1995016026A1 (en) * | 1993-12-10 | 1995-06-15 | Abbott Laboratories | Reagents and methods for the detection of methotrexate |
| GB9401182D0 (en) | 1994-01-21 | 1994-03-16 | Inst Of Cancer The Research | Antibodies to EGF receptor and their antitumour effect |
| PT1231268E (pt) | 1994-01-31 | 2005-11-30 | Univ Boston | Bancos de anticorpos policlonais |
| ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| ES2251723T3 (es) * | 1994-08-12 | 2006-05-01 | Immunomedics, Inc. | Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia. |
| EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
| GB9504344D0 (en) * | 1995-03-03 | 1995-04-19 | Unilever Plc | Antibody fragment production |
| US6091001A (en) * | 1995-03-29 | 2000-07-18 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US5641870A (en) * | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6019968A (en) * | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| EP0826034A4 (en) * | 1995-04-21 | 2002-06-19 | Cell Genesys Inc | PRODUCTION OF LARGE GENOMIC DNA DELETIONS |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| EP0850051A2 (en) | 1995-08-31 | 1998-07-01 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US5989830A (en) * | 1995-10-16 | 1999-11-23 | Unilever Patent Holdings Bv | Bifunctional or bivalent antibody fragment analogue |
| US6331431B1 (en) | 1995-11-28 | 2001-12-18 | Ixsys, Inc. | Vacuum device and method for isolating periplasmic fraction from cells |
| DK0929578T3 (da) | 1996-02-09 | 2003-08-25 | Abbott Lab Bermuda Ltd | Humane antistoffer, der binder human TNFalfa |
| DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| CA2250166A1 (en) | 1996-03-28 | 1997-10-02 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
| ES2225961T3 (es) | 1996-04-04 | 2005-03-16 | Unilever N.V. | Proteina de union a antigeno multivalente y multiespecifica. |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6986890B1 (en) * | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| DK1712623T3 (da) | 1997-01-21 | 2012-02-06 | Gen Hospital Corp | Udvælgelse af proteiner ved anvendelse af RNA-proteinfusioner |
| US6057098A (en) * | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU8691398A (en) | 1997-08-04 | 1999-02-22 | Ixsys, Incorporated | Methods for identifying ligand specific binding molecules |
| US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| AU2978899A (en) | 1998-03-03 | 1999-09-20 | Abgenix, Inc. | Cd147 binding molecules as therapeutics |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| PT1308456E (pt) | 1998-05-06 | 2007-12-03 | Genentech Inc | Purificação de anticorpos por cromatografia de permuta iónica |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| SI2168984T1 (sl) | 1999-03-25 | 2012-12-31 | Abbott Gmbh & Co. Kg | Človeška protitelesa za vezavo IL-12 in postopki izdelave |
| US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP1191944A2 (en) | 1999-06-25 | 2002-04-03 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
| EP1230269A2 (en) | 1999-11-03 | 2002-08-14 | Maxygen, Inc. | Antibody diversity generation |
| TWI335336B (https=) | 2000-02-10 | 2011-01-01 | Abbott Gmbh & Co Kg | |
| NZ520458A (en) | 2000-02-24 | 2005-02-25 | Genentech Inc | Caspase activated prodrugs therapy |
| CN1427891A (zh) | 2000-02-25 | 2003-07-02 | 美国政府由(美国)卫生和福利部部长代表 | 具有提高的细胞毒性和产量的抗EGFRvIII的scFv、基于其的免疫毒素、及其应用方法 |
| CN1423700A (zh) * | 2000-03-24 | 2003-06-11 | 麦克美特股份公司 | 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽 |
| CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
| AU5943201A (en) | 2000-05-03 | 2001-11-12 | Amgen Inc | Modified peptides as therapeutic agents |
| CN1239701C (zh) | 2000-05-19 | 2006-02-01 | 梨树化学株式会社 | 抗表皮生长因子受体的人源化抗体 |
| EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| KR100919593B1 (ko) | 2000-06-29 | 2009-09-29 | 아보트 러보러터리즈 | 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물 |
| CA2410551A1 (en) | 2000-06-30 | 2002-01-10 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) | Heterodimeric fusion proteins |
| GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| US6699473B2 (en) * | 2000-10-13 | 2004-03-02 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
| NZ526720A (en) | 2000-12-28 | 2007-11-30 | Altus Pharmaceuticals Inc | Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies |
| BRPI0116728B1 (pt) | 2001-01-05 | 2018-10-30 | Pfizer Inc. | anticorpos para receptor de fator de crescimento i semelhante à insulina |
| US7667004B2 (en) * | 2001-04-17 | 2010-02-23 | Abmaxis, Inc. | Humanized antibodies against vascular endothelial growth factor |
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| WO2002097048A2 (en) | 2001-05-30 | 2002-12-05 | Centocor, Inc. | ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| DK1401498T3 (da) * | 2001-05-30 | 2011-11-21 | Genentech Inc | Anti-NGF-antistoffer til behandlingen af forskellige sygdomme |
| NZ530212A (en) | 2001-06-13 | 2006-09-29 | Genmab As | An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR) |
| WO2003011911A1 (fr) * | 2001-07-31 | 2003-02-13 | Ono Pharmaceutical Co., Ltd. | Substance specifique pour pd-1 |
| JP2005503789A (ja) | 2001-08-17 | 2005-02-10 | イーライ・リリー・アンド・カンパニー | 抗Ａβ抗体 |
| DK1438400T3 (da) | 2001-10-01 | 2009-10-05 | Dyax Corp | Flerkædede eukaryote display-vektorer og anvendelser deraf |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| AU2002346373A1 (en) | 2001-11-09 | 2003-05-19 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
| BRPI0214168B8 (pt) * | 2001-11-14 | 2021-05-25 | Centocor Inc | anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos |
| AU2002351353A1 (en) * | 2001-12-19 | 2003-09-02 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
| AU2003210802B2 (en) * | 2002-02-05 | 2009-09-10 | Genentech Inc. | Protein purification |
| EP1573002A4 (en) | 2002-02-11 | 2008-07-16 | Genentech Inc | ANTIBODY VARIANTS WITH FASTER ANTIGEN ASSOCIATION SPEEDS |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| DK1495055T3 (da) | 2002-04-18 | 2013-11-11 | Genencor Int | Produktion af funktionelle antistoffer i filamentøse svampe |
| CA2478925C (en) | 2002-04-26 | 2016-06-07 | Robert Lee Fahrner | Non-affinity purification of proteins |
| US20030206898A1 (en) * | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| JP4335130B2 (ja) * | 2002-04-30 | 2009-09-30 | 協和発酵キリン株式会社 | ヒトインスリン様成長因子に対する抗体 |
| US7217796B2 (en) | 2002-05-24 | 2007-05-15 | Schering Corporation | Neutralizing human anti-IGFR antibody |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| CA2496419A1 (en) * | 2002-08-19 | 2004-02-26 | Abgenix, Inc. | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| SI1543038T2 (sl) | 2002-09-11 | 2020-12-31 | Genentech, Inc. | Čiščenje proteinov |
| EP3263596A1 (en) * | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| CN101014364B (zh) * | 2002-12-24 | 2012-01-18 | 里纳特神经系统学公司 | 抗ngf抗体及其使用方法 |
| CA2513113A1 (en) * | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| ES2532399T3 (es) | 2003-03-05 | 2015-03-26 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
| WO2005016970A2 (en) | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
| CA2522586C (en) * | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| KR101254371B1 (ko) | 2003-07-18 | 2013-05-02 | 암젠 프레몬트 인코포레이티드 | 간세포 성장인자에 결합하는 분리된 항체 |
| EP1648940B1 (en) * | 2003-07-28 | 2016-04-27 | Genentech, Inc. | Reducing protein a leaching during protein a affinity chromatography |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US7662928B2 (en) * | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| WO2005035575A2 (en) | 2003-08-22 | 2005-04-21 | Medimmune, Inc. | Humanization of antibodies |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
| CN1930304B (zh) * | 2003-11-21 | 2016-01-06 | Anp技术公司 | 不对称支化的聚合物缀合物和微阵列检测 |
| CA2548817A1 (en) * | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| EP1737969B2 (en) | 2004-04-15 | 2018-09-12 | GlycoFi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| EP1773885B1 (en) * | 2004-08-05 | 2010-04-21 | Genentech, Inc. | Humanized anti-cmet antagonists |
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| KR20070057839A (ko) | 2004-08-19 | 2007-06-07 | 제넨테크, 인크. | 변경된 이펙터 기능을 갖는 폴리펩티드 변이체 |
| GB0419424D0 (en) | 2004-09-02 | 2004-10-06 | Viragen Scotland Ltd | Transgene optimisation |
| RS52213B (sr) * | 2004-09-03 | 2012-10-31 | Genentech, Inc. | Humanizovani anti-beta7 antagonisti i njihove primene |
| AU2005291486A1 (en) * | 2004-10-01 | 2006-04-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Novel antibodies directed to the mammalian EAG1 ion channel protein |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| US20060253100A1 (en) * | 2004-10-22 | 2006-11-09 | Medtronic, Inc. | Systems and Methods to Treat Pain Locally |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| BRPI0519596B1 (pt) * | 2004-12-21 | 2022-01-18 | Astrazeneca Ab | Agente de ligação alvejado, anticorpo monoclonal que se liga a angiopoietina-2, molécula de ácido nucleico, vetor, e, uso do agente de ligação alvejado |
| EP1851245B1 (en) * | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
| KR101335798B1 (ko) * | 2005-02-15 | 2013-12-02 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| EP2447281B1 (en) | 2005-03-24 | 2015-12-16 | ThromboGenics N.V. | Novel anti-PLGF antibody |
| EP1874824A4 (en) * | 2005-04-06 | 2009-12-30 | Ibc Pharmaceuticals Inc | METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF |
| DK1888113T3 (da) * | 2005-05-27 | 2014-09-01 | Biogen Idec Inc | Tweak-bindende antistoffer |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| KR20130108481A (ko) * | 2005-08-19 | 2013-10-02 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| CA2619298C (en) * | 2005-08-26 | 2017-07-04 | Glycart Biotechnology Ag | Modified antigen binding molecules with altered cell signaling activity |
| US7906116B2 (en) | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| JP2009508970A (ja) * | 2005-09-21 | 2009-03-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 疼痛の局所造影および治療のためのシステム、組成物並びに方法 |
| AU2006301492B2 (en) | 2005-10-11 | 2011-06-09 | Amgen Research (Munich) Gmbh | Compositions comprising cross-species-specific antibodies and uses thereof |
| WO2007048849A1 (en) | 2005-10-28 | 2007-05-03 | Novo Nordisk A/S | Fusion proteins that bind effector lymphocytes and target cells |
| UA96139C2 (uk) | 2005-11-08 | 2011-10-10 | Дженентек, Інк. | Антитіло до нейропіліну-1 (nrp1) |
| ES2385054T3 (es) * | 2005-12-13 | 2012-07-17 | Medimmune Limited | Proteínas de unión específicas para factores de crecimiento de tipo insulina y usos de las mismas |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| KR101516823B1 (ko) * | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| MX2008012023A (es) * | 2006-03-21 | 2008-10-01 | Wyeth Corp | Metodos para prevenir y tratar enfermedades amiloidogenicas. |
| US20070232556A1 (en) * | 2006-03-31 | 2007-10-04 | Montine Thomas J | Methods and compositions for the treatment of neurological diseases and disorders |
| BRPI0709977A2 (pt) | 2006-04-14 | 2011-08-02 | Novartis Ag | uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos |
| MX2008013508A (es) | 2006-04-21 | 2008-10-31 | Novartis Ag | Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40. |
| US20080118978A1 (en) * | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| CN101058609B (zh) | 2006-05-26 | 2011-04-13 | 神州细胞工程有限公司 | 人源抗体及其表达 |
| AR061170A1 (es) * | 2006-06-02 | 2008-08-06 | Aveo Pharmaceuticals Inc | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) |
| KR20090016762A (ko) * | 2006-06-06 | 2009-02-17 | 제넨테크, 인크. | 혈관 발달을 조정하기 위한 조성물 및 방법 |
| EA018260B1 (ru) | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| CN106188303A (zh) * | 2006-11-02 | 2016-12-07 | 健泰科生物技术公司 | 人源化的抗‑d因子抗体 |
| AU2007338734A1 (en) | 2006-12-20 | 2008-07-03 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| US7919594B2 (en) * | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| PT2125894T (pt) * | 2007-03-22 | 2019-02-27 | Biogen Ma Inc | Proteínas de ligação incluindo anticorpos, derivados de anticorpos e fragmentos de anticorpos que se ligam especificamente ao cd154 e as suas utilizações |
| BRPI0810561A2 (pt) * | 2007-04-23 | 2019-09-24 | Wyeth Corp | métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13. |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| WO2009003142A1 (en) * | 2007-06-27 | 2008-12-31 | The Board Of Trustees Of The Leland, Stanford Junior University | Beta2-microglobulin and c reactive protein (crp) as biomarkers for peripheral artery disease |
| KR20100058509A (ko) * | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| CA2702611A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| BRPI0910482A2 (pt) | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| BRPI0913366A8 (pt) | 2008-06-03 | 2017-07-11 | Abbott Lab | Imunoglobulinas de domínio variável duplo e seus usos |
| PE20100092A1 (es) | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
| NZ603698A (en) | 2008-07-08 | 2014-03-28 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| WO2010006059A1 (en) * | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 binding proteins and uses thereof |
| MX2011005953A (es) | 2008-12-04 | 2011-08-17 | Abbott Lab | Inmunoglobulinas de dominio variable dual y usos de las mismas. |
| EP2403531A4 (en) * | 2009-03-05 | 2013-02-27 | Abbott Lab | IL-17 BINDING PROTEINS |
| EP2424566A4 (en) | 2009-05-01 | 2013-07-31 | Abbvie Inc | IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE |
| NZ596711A (en) * | 2009-05-01 | 2013-11-29 | Dual variable domain immunoglobulins and uses thereof | |
| UY32808A (es) | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| KR20120060877A (ko) * | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| AU2010306677B2 (en) * | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| IN2012DN02634A (https=) * | 2009-10-15 | 2015-09-04 | Abbvie Inc | |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| RU2013103060A (ru) * | 2010-06-24 | 2014-07-27 | Эббви Инк. | Иммуноглобулины с двумя вариабельными доменами и их применение |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8735546B2 (en) * | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| PE20140229A1 (es) * | 2010-08-26 | 2014-03-27 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US20120263722A1 (en) * | 2010-11-04 | 2012-10-18 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
-
2010
- 2010-09-01 KR KR1020127008445A patent/KR20120060877A/ko not_active Withdrawn
- 2010-09-01 BR BR112012004710A patent/BR112012004710A2/pt not_active IP Right Cessation
- 2010-09-01 UY UY0001032870A patent/UY32870A/es not_active Application Discontinuation
- 2010-09-01 SG SG2012014411A patent/SG178602A1/en unknown
- 2010-09-01 RU RU2012112550/10A patent/RU2012112550A/ru not_active Application Discontinuation
- 2010-09-01 EP EP10814433.8A patent/EP2473524A4/en not_active Withdrawn
- 2010-09-01 AR ARP100103210A patent/AR078254A1/es not_active Application Discontinuation
- 2010-09-01 JP JP2012527113A patent/JP2013503607A/ja not_active Withdrawn
- 2010-09-01 US US12/873,926 patent/US8586714B2/en active Active
- 2010-09-01 PE PE2012000278A patent/PE20121530A1/es not_active Application Discontinuation
- 2010-09-01 WO PCT/US2010/047543 patent/WO2011028811A2/en not_active Ceased
- 2010-09-01 IN IN2737DEN2012 patent/IN2012DN02737A/en unknown
- 2010-09-01 AU AU2010289527A patent/AU2010289527C1/en not_active Ceased
- 2010-09-01 TW TW099129545A patent/TW201119673A/zh unknown
- 2010-09-01 CN CN2010800491395A patent/CN102612524A/zh active Pending
- 2010-09-01 MX MX2012002651A patent/MX2012002651A/es not_active Application Discontinuation
- 2010-09-01 CA CA2772628A patent/CA2772628A1/en not_active Abandoned
- 2010-09-01 NZ NZ598929A patent/NZ598929A/en not_active IP Right Cessation
-
2012
- 2012-02-29 IL IL218402A patent/IL218402A0/en unknown
- 2012-03-01 GT GT201200058A patent/GT201200058A/es unknown
- 2012-03-01 DO DO2012000055A patent/DOP2012000055A/es unknown
- 2012-03-01 CL CL2012000559A patent/CL2012000559A1/es unknown
- 2012-03-14 EC ECSP12011730 patent/ECSP12011730A/es unknown
- 2012-03-20 CO CO12047117A patent/CO6511254A2/es unknown
- 2012-03-27 CR CR20120154A patent/CR20120154A/es unknown
- 2012-03-28 ZA ZA2012/02268A patent/ZA201202268B/en unknown
-
2013
- 2013-10-17 US US14/056,116 patent/US20140134171A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503607A5 (https=) | ||
| JP2013500721A5 (https=) | ||
| JP2013507969A5 (https=) | ||
| JP2013537415A5 (https=) | ||
| JP2012525441A5 (https=) | ||
| JP2013509189A5 (https=) | ||
| JP2013507928A5 (https=) | ||
| JP2014504860A5 (https=) | ||
| JP2012500621A5 (https=) | ||
| JP2011523853A5 (https=) | ||
| JP2011523400A5 (https=) | ||
| JP2013539364A5 (https=) | ||
| JP2011527580A5 (https=) | ||
| RU2011104348A (ru) | Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение | |
| JP2012525155A5 (https=) | ||
| JP2012519708A5 (https=) | ||
| RU2015143833A (ru) | СВЯЗЫВАЮЩИЕ БЕЛКИ С ДВОЙНОЙ СПЕЦИФИЧНОСТЬЮ, НАПРАВЛЕННЫЕ ПРОТИВ TNFα | |
| RU2013133811A (ru) | Иммуноглобулины с двойными вариабельными доменами и их применения | |
| RU2013109275A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение | |
| JP2016047820A5 (https=) | ||
| RU2012107526A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение | |
| RU2012121189A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение | |
| RU2010153580A (ru) | Иммуноглобулины с двумя вариабельными доменами и их применение | |
| RU2010153578A (ru) | Иммуноглобулины с двойными вариабельными доменами и их применение | |
| WO2011047262A4 (en) | Dual variable domain immunoglobulins and uses thereof |